Papillary cystadenoma of epididymis: Is there a need for further investigation in unilateral cases?

Chrysovalantis Toutziaris a, Spyridon Kampantais a,*, Ioannis Perdiskis a, Victoras Gourvas b, Leonidas Laskaridis a, Konstantinos Gkagkalidis a, Sotiris Lakis b, Stavros Ioannidis a

a 1st Department of Urology, Aristotle University of Thessaloniki, Thessaloniki 54635, Greece
b Department of Pathology, “G.Gennimatas” General Hospital, Thessaloniki 54635, Greece

ARTICLE INFO
Article history:
Received 23 November 2012
Received in revised form 14 March 2013
Accepted 20 March 2013
Available online 17 April 2013

Keywords:
Epididymis
Papillary cystadenoma
von Hippel–Lindau disease

ABSTRACT
INTRODUCTION: The presence of a mass in the epididymis is not a common entity. The papillary cystadenoma of epididymis is a benign tumor which may occur sporadically or as a characteristic of von Hippel–Lindau disease.

PRESENTATION OF CASE: We present a case of a 27-year-old man with a right scrotal mass who was treated with surgical excision. Histopathological examination revealed a clear cell epididymal papillary cystadenoma. A computed tomography scan that was performed later showed no other abnormality or any signs of von Hippel–Lindau disease.

DISCUSSION: In this report, a case of a young man suffering from this rare tumor is discussed, focusing on the need of further evaluation in order to determine if it occurs as a feature of VHL disease or as a sporadic form.

CONCLUSION: In unilateral cases of papillary cystadenoma of epididymis such as our patient’s, literature advocates that no further examinations and expensive genetic testing is required.

© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

1. Introduction

The most common neoplasm of the epididymis is a benign mass called “adenomatoid tumor” 1. The papillary cystadenoma (PCE) is the second most common benign neoplasm 2 while leiomyomas 3 and lipomas 4 follow in frequency and it may occur sporadically or as a characteristic of von Hippel–Lindau disease (VHL) 3. PCE was first described in 1956 by Sherrick in a 21-year-old patient 2; since then, approximately 60 reports of such tumors have been published 5. We discuss a case of a young man suffering from this rare tumor, focusing on the need of further evaluation in order to determine if it occurs as a feature of VHL disease or as a sporadic form.

2. Case presentation

A 27-year-old man presented to our department complaining of a mild pain in his right scrotum. According to the patient’s history, a small enlargement of the right epididymal had been noticed 3 months ago. The first clinical diagnosis was suggestive of epididymitis so he was treated initially with antibiotics for 3 weeks. However, one week after the conclusion of the initial therapy, no improvement was mentioned.

A scrotal ultrasound was performed revealing a well-circumscribed mass with a complex echo pattern, contiguous to the head of the right epididymis. Power Doppler indicated increased tumor vascularity (Fig. 1). Unfortunately, no definite diagnosis could be reached through imaging, so diagnostic surgery was mandatory.

Under general anesthesia, a 3 cm well-circumscribed tumor was excised along with the right epididymis (Fig. 2). Macroscopically, the tumor was hemorrhagic with microcystic consistency and it had a golden yellow hue (Fig. 3). The patient’s recovery was uneventful. Histopathological examination revealed a clear cell papillary cystadenoma consisted of clear cells in a papillary–tubular pattern, mimicking a clear cell renal carcinoma (Fig. 4). The tumor’s morphology, its close relationship with the epididymis, the presence of a fibrous capsule and the immunohistochemical results which were positive for Vimentin, Cytokeratin AE1/AE3, Cytokeratins 7 and 20, while it was negative for CD-10, CEA and p53, determined the final diagnosis.

An abdominal CT scan was performed one month after the surgery and a second one, twelve months later. Neither of them revealed any abnormality or any signs of VHL.

3. Discussion

PCE may occur as a manifestation of VHL or sporadically (60%), mimicking a clear cell renal carcinoma (RCC). 5 VHL is a dominant autosomal neoplasia syndrome, resulting from a germline mutation...
In the VHL gene. Patients suffering from this syndrome are at risk of developing various benign and malignant tumors of the central nervous system, adrenal glands, pancreas, reproductive adnexal organs and kidneys. The most common histological type of RCC is the clear cell type and is reported to develop in 24–45% of patients with VHLD. The mean age of patients with RCC associated with the VHLD is 37 years, an age at which both RCC and clear cell papillary cystadenoma are viable considerations in the differential diagnosis of an epididymal or mesosyalpingeal clear cell tumor.

In the majority of cases, PCE develops within the efferent ductules of the head of the epididymis as a partially or completely cystic or solid lesion measuring about 1–3 cm in diameter and is usually asymptomatic. However, in symptomatic patients the most common presentation is a painless, slowly growing, scrotal swelling. In rare occasions, they may present with pain or tenderness in the scrotum or are found to have an epididymal nodule during an examination for infertility. The ages of occurrence are 16–65 with a mean age of 36. In females, the counterpart of papillary cystadenoma of the epididymis is represented by papillary tumors of the broad ligament and peritoneum most of whom are usually solid, although they may have distinct cystic spaces. Distinctive microscopic features were described by Price. Allelic loss of the VHL gene, located on the short arm of chromosome 1 has been demonstrated in all benign papillary tumors developing in VH patients (papillary cystadenoma of the broad ligament, endometrioid cystadenoma of the broad ligament, papillary cystadenomas of the epididymis, papillary tumor of the retroperitoneum). Several hypoxia-inducible genes are regulated by protein encoded by the VHL gene, including platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), erythropoietin, and vascular endothelial growth factor (VEGF). VEGF overexpression has been demonstrated in VHL-associated tumors and may explain the cyst formation and vascularized stroma present in these tumors. Odrywolski and Mukhopadhyay analyzed in a review 58 cases of PCE reported in the literature. They found that bilateral PCE is highly associated with VHLD. Two thirds of patients with bilateral tumor had stigmas or were found to be VHLD positive. On the other hand, the association of unilateral PCE with VHLD is weaker (20.3%).

A dilemma arises at this point concerning the patients with unilateral PCE tumors. Should we investigate the chance they have an undiscovered VHLD or stop any further examination? Price et al. studied 8 patients which were followed up for a long period, with intervals ranging from 18 months to 15 years. Among them no one developed VHLD. Furthermore, unilateral PCE has never been reported as the initial presentation of VHLD. The above data advocate that no further examinations and expensive genetic testing is required in the treatment of unilateral PCE tumors.

Interestingly, the histological differentiation between PCE and metastatic renal cell carcinoma in epididymis can be difficult.
Both are known to develop in von Hippel–Lindau syndrome; they both have similar origin from meso-metanephric tissue and they are both related to VHL protein function which may disrupt tumor suppression through hypoxia-inducible factor (HIF) stimulation of angiogenesis. This may be a possible explanation of the high vascularity of the VHLD-associated tumors. Lectin histochemistry studies are helpful in distinguishing between papillary cystadenoma and metastatic renal cell carcinoma in epididymis thus a routine examination of kidneys is not always necessary.

4. Conclusion

The discovery of a benign lesion in epididymis, like a papillary cystadenoma, although rare, is still possible. It may occur sporadically or as a manifestation of VHLD; however, in the case of VHLD, the PCE is usually bilateral. In unilateral cases of PCE such as our patient’s, literature reviews provide evidence against extensive and expensive genetic testing for VHLD.

Conflict of interest

None declared.

Funding

None.

Ethical approval

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author’s contributions

Chrysovalantis Toutziaris: drafting the article, critical revision of the article and final approval of the version to be published.

Spyridon Kampantas: conception and design, acquisition of data, analysis and interpretation of data. Ioannis Perdikis: acquisition of data. Victorias Gourvas: acquisition of data. Leonidas Laskaridis: analysis and interpretation of data. Konstantinos Gagakalis: critical revision of the article. Sotiris Lakis: acquisition of data. Stavros Ioannidis: final approval of the version to be published.

References

1. Kuhn MT, Maclennan GT. Benign neoplasms of the epididymis. Journal of Urology 2005;174:723–6.
2. Sherrick JC. Papillary cystadenoma of the epididymis. Cancer 1956;9:403–7.
3. Longo VJ, McDonald JR, Thompson GJ. Primary neoplasms of the epididymis. Journal of the American Medical Association 1951;147:937–41.
4. Hinman F, Gibson TE. Tumors of the epididymis, seminal cord and testicular tunics. Archives of Surgery 1924;8:100–37.
5. Odryzwołski KJ, Mukhopadhyay S. Papillary cystadenoma of the epididymis. Archives of Pathology and Laboratory Medicine 2010;134:630–3.
6. Aydin H, Young RH, Ronnett BM, Epslan JI. Clear papillary cystadenoma of the epididymis and mesosalpinx: immunohistochemical differentiation from metastatic clear cell carcinoma. American Journal of Surgical Pathology 2005;29:520–3.
7. Tsuda H, Fukushima S, Takahashi M, Hikosaka Y, Hayashi K. Familial bilateral papillary cystadenoma of the epididymis. Report of three cases in siblings. Cancer 1976;37:1831–9.
8. Wernert N, Goebbel S, Prediger L. Papillary cystadenoma of epididymis. Case report and review of literature. Pathology, Research and Practice 1986;181:260–4.
9. Price Jr EB. Papillary cystadenoma of the epididymis. A clinicopathologic analysis of 20 cases. Archives of Pathology 1971;91(5):456–70.
10. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel–Lindau mutation in clear cell papillary cystadenoma of the epididymis. Human Pathology 1995;26:1341–6.
11. Leung SY, Chan AS, Wong MP, Yuen ST, Fan YW, Chung LP. Expression of vascular endothelial growth factor in von Hippel–Lindau syndrome-associated papillary cystadenoma of the epididymis. Human Pathology 1998;29:1322–4.
12. Krangel PJ, Pestaner J, Travis WD, Linehan WM, Filling-Katz MR. Papillary cystadenoma of the epididymis. A report of three cases with lectin histochemistry. Archives of Pathology and Laboratory Medicine 1990;114:672–5.
13. Price Jr EB. Papillary cystadenoma of the epididymis. A clinicopathologic analysis of 20 cases. Archives of Pathology 1971;91:456–70.
14. Shen T, Zhuang Z, Gersell DJ, Tavassoli FA. Allelic deletion of VHL gene detected in papillary tumors of the broad ligament, epididymis, and retroperitoneum in von Hippel–Lindau disease patients. International Journal of Surgical Pathology 2000;8:207–12.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.